» Articles » PMID: 1250281

Interaction of Quinidine with Anticonvulsant Drugs

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1976 Mar 25
PMID 1250281
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Drug-disposition studies of orally administered quinidine in four normal healthy volunteers indicated that phenobarbital and phenytoin reduced the half-life of quinidine by approximately 50 per cent (control, 3.0 to 6.1 hours, and with anticonvulsants, 1.6 to 2.6 hours). Alterations of similar magnitude in the apparent plasma clearance of quinidine after oral administration (control 20.0 to 32.0 liters per hour; with anticonvulsant 44.0 to 94.0 liters per hour) suggest that this effect is probably due to an increase in the rate of metabolism of quinidine, although decreased absorption cannot be entirely ruled out. In two index patients the concomitant use of anticonvulsant drugs resulted in inadequate blood levels of quinidine with standard dosages of that drug.

Citing Articles

Therapeutic Drug Monitoring of Quinidine in Pediatric Patients with Genetic Variants.

Ferretti A, Simeoli R, Cairoli S, Pietrafusa N, Trivisano M, Vici C Pharmaceutics. 2022; 14(10).

PMID: 36297665 PMC: 9608568. DOI: 10.3390/pharmaceutics14102230.


Concurrent Quinidine and Phenobarbital in the Treatment of a Patient with 2 Mutations.

Passey C, Erramouspe J, Castellanos P, ODonnell E, Denton D Curr Ther Res Clin Exp. 2019; 90:106-108.

PMID: 31388363 PMC: 6677567. DOI: 10.1016/j.curtheres.2019.02.002.


Treatment Responsiveness in KCNT1-Related Epilepsy.

Fitzgerald M, Fiannacca M, Smith D, Gertler T, Gunning B, Syrbe S Neurotherapeutics. 2019; 16(3):848-857.

PMID: 31054119 PMC: 6694367. DOI: 10.1007/s13311-019-00739-y.


Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model.

Almond L, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O Drug Metab Dispos. 2016; 44(6):821-32.

PMID: 27026679 PMC: 4885489. DOI: 10.1124/dmd.115.066845.


Quinidine in the treatment of KCNT1-positive epilepsies.

Mikati M, Jiang Y, Carboni M, Shashi V, Petrovski S, Spillmann R Ann Neurol. 2015; 78(6):995-9.

PMID: 26369628 PMC: 4811613. DOI: 10.1002/ana.24520.